Section 5: Patient Safety and Quality Assurance

5PSQ-077

COST-EFFECTIVENESS OF BIOSIMILAR ETANERCEPT IN CLINICAL PRACTICE USE

5PSQ-076

SWITCHING BIOLOGIC TREATMENTS: EXPERIENCE OF A REGIONAL HOSPITAL

5PSQ-075

INTRODUCTION OF BIOSIMILAR ETANERCEPT: AN ITALIAN DISTRICT ANALYSIS

5PSQ-074

CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER AND SECONDARY AMYLOIDOSIS: A CASE REPORT

5PSQ-073

MUCORMYCOSIS INDUCED BY INAPPROPIATE USE OF ORAL CORTICOIDS – A CASE REPORT

5PSQ-072

ACUTE PROMYELOCYTIC LEUKAEMIA AFTER INFLIXIMAB THERAPY IN A CROHN'S DISEASE PATIENT: A CASE REPORT AND A REVIEW OF THE LITERATURE

5PSQ-071

EVALUATION OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

5PSQ-070

INFLUENCE OF PATHOLOGY IN INJECTION PAIN REDUCTION WITH A NEW FORMULATION OF ORIGINAL ADALIMUMAB

5PSQ-069

ABSTRACT WITHDRAWN

5PSQ-068

ADHERENCE TO DISEASE-MODIFYING THERAPIES IN SPANISH PATIENTS WITH MULTIPLE SCLEROSIS

5PSQ-067

DETECTION OF ADVERSE NEUROPSYCHIATRIC REACTIONS ASSOCIATED WITH ABIRATERONE AND ENZALUTAMIDE TREATMENTS IN THE HOSPITAL

5PSQ-066

THE OTHER SIDE OF IMMUNOTHERAPY: SAFETY AND TOXICITY MANAGEMENT IN CLINICAL PRACTICE

5PSQ-065

MANIC SYMPTOMATOLOGY INDUCED BY ALECTINIB: A CASE REPORT

5PSQ-064

INTENSIVE MONITORING OF AFATINIB – CASE REPORT

5PSQ-063

MORE RISK OF NEUTROPAENIA IN OBESE PATIENTS TREATED WITH PACLITAXEL?

Pages